Dx Deals: BD Laboratory Business Is Up for Grabs in Bold Move
Becton Dickinson divisions responsible for $3.4 billion in annual revenue are on the block
Keeps You Up-to-Date on Lab Business and Competitive Strategy, Market Trends and Opportunities, and M&A and Investment Activity in Today’s Diagnostic Lab Industry
Becton Dickinson divisions responsible for $3.4 billion in annual revenue are on the block
With strikes increasing across industries, what happens if workers involved in the ancillary services labs depend on go on strike?
$152.1 million SYNLAB deal is expected to create a new channel for Labcorp to market its sophisticated specialty assays
CEO Laurie Menser discusses the Association for Molecular Pathology’s court case against the FDA’s rule on laboratory-developed tests.
Why ongoing coaching and learning is required for laboratory sales reps—even experienced ones—to help labs meet their business goals
The rounds of funding to Clarapath, PreciseDx, and Precision Epigenomics come at a time when other M&A activity is seasonally slow
The agency has approved fewer than 10 tests in the past three years, but a new pipeline of AI-powered products is expected to emerge soon
A guide to understanding, implementing, and benefiting from digital pathology and artificial intelligence in the clinical lab
What labs need to know about keeping patients’ data safe when using digital pathology and artificial intelligence-based solutions
Lee Fleisher, MD, advocates for clearer interpretation of test results by medical laboratory scientists
Direct-to-consumer (DTC) genetic testing has risen in popularity in recent years—but is it all it’s cracked up to be?